The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Immunomedics
 
Employment - Immunomedics
TROPHY-U-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy.
 
Scott T. Tagawa
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Dendreon; Endocyte; Genentech; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; QED Therapeutics; Sanofi; Tolmar
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi
 
Daniel Peter Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Lilly; Medivation; Millennium; Pfizer; Roche; Sanofi; TYME
Research Funding - Agensys; Astellas Medivation; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Endocyte; Genentech; Innocrin Pharma; Johnson & Johnson; Lilly; MedImmune; Merck; Millennium; Novartis; Pfizer; Progenics; Roche; Sanofi; Seagen; Sotio
Expert Testimony - Celgene; sanofi
 
Petros Grivas
Consulting or Advisory Role - AstraZeneca; Biocept; Bristol-Myers Squibb; Clovis Oncology; Driver, Inc; EMD Serono; Foundation Medicine; Genentech; HERON; Janssen; Merck; Pfizer; QED Therapeutics; Seagen
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Oncogenex (Inst); Pfizer (Inst)
 
Neeraj Agarwal
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; EMD Serono; Exelixis; Foundation One Inc; Genentech/Roche; Lilly; Medivation/Astellas; Merck; Nektar; Novartis; Pfizer; Pharmacyclics
Research Funding - Active Biotech (Inst); Amgen (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Cora N. Sternberg
Honoraria - Astellas Pharma; AstraZeneca; Ipsen; Janssen; Pfizer; Sanofi
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; Incyte; Ipsen; MSD; Novartis; Pfizer; Roche; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Aveo (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Genzyme (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Myovant Sciences (Inst); Nektar (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
 
Chris Hernandez
No Relationships to Disclose
 
Peggy Siemon-Hryczyk
Employment - Immunomedics
 
Trishna Goswami
No Relationships to Disclose
 
Yohann Loriot
Honoraria - Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Incyte; Janssen; Janssen (Inst); MSD Oncology; MSD Oncology (Inst); Roche; Seagen
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); CureVac (Inst); Exelixis (Inst); Incyte (Inst); Janssen Oncology (Inst); Medivation (Inst); MSD Oncology (Inst); Oncogenex (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche